Basiliximab

BNF:: 8.2.2
Status:: Red
Decision Date:: None

Comments

RED:

NICE TA481: Immunosuppressive therapy for kidney transplant in adults. (Includes basiliximab or immediate-release tacrolimus or mycophenolate mofetil). (Decision date - November 2017)
NICE TA482: Immunosuppressive therapy for children and young people. (Includes basiliximab or immediate-release tacrolimus or mycophenolate mofetil). (Decision date - November 2017)

NHS England drug. To be used in line with NHS England commissioning intentions.

Red Drug Classifications

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)